A case of idiopathic portal vein thrombosis?
CLINICAL PRESENTATION
A 21-year-old Caucasian male presented with a short history of epigastric pain and weight loss. Physical examination revealed splenomegaly only. Renal biochemistry and full blood count were normal. There were minor elevations in liver enzymes. A contrastenhanced abdominal CT scan identified splenomegaly with infarcts, and portal and splenic vein thrombosis without cavernoma formation (figs 1 and 2). A thrombophilia screen comprising anticardiolipin immunoglobulin G (IgG) and lupus anticoagulant, factor V Leiden and prothrombin gene mutation analysis, protein C and S quantification and screening for paroxysmal nocturnal haemoglobinuria was normal. Bone marrow architecture was normal, with a non-significant increase in megakaryocyte count. The BCR-ABL oncogene was absent.
The patient was anticoagulated and monitored as an outpatient. The liver biochemistry normalised and full blood counts remained persistently normal. Figures 3 and 4 are from a repeat CT scan performed 3 years after the initial presentation. Editor
As indicated by the arrows, figs 5 and 6 demonstrate the formation of a portal venous cavernoma and collateral circulation. There is persistent splenomegaly with resolution of the initial splenic infarcts.
Hypersplenism and increased plasma volume following a portal vein thrombosis (PVT) can limit the ability of conventional criteria to diagnose an underlying myeloproliferative disorder.
1 Janus-activating kinase 2 (JAK2) mediates erythropoietin receptor signal transmission in haematopoietic cells. The V617F mutation of JAK2, first described in 2005, 2 affords haematopoietic cells an uncontrolled proliferative and survival advantage. The mutation is diagnostic of a myeloproliferative disorder, and is present in ,95% of patients with polycythaemia vera and 50% of essential thrombocythaemia and idiopathic myelofibrosis.
3 Twenty-one per cent of patients with an otherwise idiopathic PVT have the V617F mutation. 1 This patient had the V617F mutation, and hence was diagnosed with a non-overt myeloproliferative disorder. These patients require close follow-up due to the high development rate of an overt myeloproliferative disorder. 4 As warfarin may fail to fully prevent further thromboses following a PVT, patients with the mutation may potentially benefit from combined aspirin and warfarin therapy. 5 It is known that patients with varices and underlying cirrhosis have a fourfold increased risk of portal hypertensive bleeding following use of .300 mg of aspirin per day. 6 The authors are not aware of any published data on the bleeding risk of low-dose aspirin in the setting of non-cirrhotic portal hypertension.
Acute variceal haemorrhage occurred 4 months after starting combined low-dose aspririn/warfarin treatment. This was despite the prophylactic use of propranolol and a proton pump inhibitor. The episode was successfully managed with band ligation and aspirin was discontinued. To date, there has been no recurrence of bleeding or further thrombosis. 
